TWI659210B - 加強腫瘤生長的方法 - Google Patents
加強腫瘤生長的方法 Download PDFInfo
- Publication number
- TWI659210B TWI659210B TW103127591A TW103127591A TWI659210B TW I659210 B TWI659210 B TW I659210B TW 103127591 A TW103127591 A TW 103127591A TW 103127591 A TW103127591 A TW 103127591A TW I659210 B TWI659210 B TW I659210B
- Authority
- TW
- Taiwan
- Prior art keywords
- nme7
- cells
- human
- cancer cells
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 131
- 230000004614 tumor growth Effects 0.000 title description 25
- 230000002708 enhancing effect Effects 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 569
- 201000011510 cancer Diseases 0.000 claims abstract description 442
- 238000012360 testing method Methods 0.000 claims abstract description 63
- 241000124008 Mammalia Species 0.000 claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 516
- 210000000130 stem cell Anatomy 0.000 claims description 284
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims description 237
- 108090000623 proteins and genes Proteins 0.000 claims description 214
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims description 197
- 241001465754 Metazoa Species 0.000 claims description 146
- 102100034256 Mucin-1 Human genes 0.000 claims description 128
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 124
- 102000004169 proteins and genes Human genes 0.000 claims description 116
- 239000003795 chemical substances by application Substances 0.000 claims description 93
- 230000009261 transgenic effect Effects 0.000 claims description 50
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 39
- 102000000905 Cadherin Human genes 0.000 claims description 38
- 108050007957 Cadherin Proteins 0.000 claims description 38
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 claims description 38
- 101000883749 Homo sapiens Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 claims description 38
- 239000003102 growth factor Substances 0.000 claims description 38
- 102100023962 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 Human genes 0.000 claims description 37
- 108091005625 BRD4 Proteins 0.000 claims description 36
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 36
- 101000975541 Homo sapiens Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 Proteins 0.000 claims description 36
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 claims description 36
- 101000615495 Homo sapiens Methyl-CpG-binding domain protein 3 Proteins 0.000 claims description 35
- 210000001082 somatic cell Anatomy 0.000 claims description 35
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 claims description 34
- 102000057860 human MUC1 Human genes 0.000 claims description 34
- 241000283984 Rodentia Species 0.000 claims description 24
- 210000004602 germ cell Anatomy 0.000 claims description 24
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 23
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 23
- 230000001939 inductive effect Effects 0.000 claims description 20
- 239000000178 monomer Substances 0.000 claims description 16
- 239000012679 serum free medium Substances 0.000 claims description 16
- 238000010171 animal model Methods 0.000 claims description 12
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 194
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 149
- 239000000539 dimer Substances 0.000 description 126
- 241000699670 Mus sp. Species 0.000 description 122
- 230000001580 bacterial effect Effects 0.000 description 75
- 108020004414 DNA Proteins 0.000 description 72
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 57
- 230000014509 gene expression Effects 0.000 description 54
- 241000588724 Escherichia coli Species 0.000 description 49
- 239000003814 drug Substances 0.000 description 49
- 239000002609 medium Substances 0.000 description 49
- 229940079593 drug Drugs 0.000 description 48
- 238000005259 measurement Methods 0.000 description 48
- 206010006187 Breast cancer Diseases 0.000 description 46
- 208000026310 Breast neoplasm Diseases 0.000 description 46
- 238000002347 injection Methods 0.000 description 46
- 239000007924 injection Substances 0.000 description 46
- 102000052119 human NME1 Human genes 0.000 description 45
- 208000037819 metastatic cancer Diseases 0.000 description 44
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 44
- 239000003112 inhibitor Substances 0.000 description 43
- 101001128739 Homo sapiens Nucleoside diphosphate kinase 6 Proteins 0.000 description 42
- 230000012010 growth Effects 0.000 description 42
- 238000003757 reverse transcription PCR Methods 0.000 description 42
- 102000043772 human NME7 Human genes 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- 150000001413 amino acids Chemical class 0.000 description 35
- 108090000765 processed proteins & peptides Proteins 0.000 description 32
- 238000002054 transplantation Methods 0.000 description 32
- 230000001464 adherent effect Effects 0.000 description 30
- 230000001394 metastastic effect Effects 0.000 description 29
- 102000044316 human NME6 Human genes 0.000 description 28
- 210000002950 fibroblast Anatomy 0.000 description 27
- 239000001963 growth medium Substances 0.000 description 27
- 108010082117 matrigel Proteins 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 210000004881 tumor cell Anatomy 0.000 description 25
- 206010027476 Metastases Diseases 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 229940043355 kinase inhibitor Drugs 0.000 description 23
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 23
- 230000009401 metastasis Effects 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 20
- 206010060862 Prostate cancer Diseases 0.000 description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 20
- 238000002513 implantation Methods 0.000 description 20
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 19
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 16
- 230000010261 cell growth Effects 0.000 description 15
- 238000007667 floating Methods 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 102000009465 Growth Factor Receptors Human genes 0.000 description 14
- 108010009202 Growth Factor Receptors Proteins 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- 102100032113 Nucleoside diphosphate kinase 6 Human genes 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 13
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 13
- 231100000419 toxicity Toxicity 0.000 description 13
- 230000001988 toxicity Effects 0.000 description 13
- 108010077544 Chromatin Proteins 0.000 description 12
- 210000003483 chromatin Anatomy 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 230000008707 rearrangement Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 210000005102 tumor initiating cell Anatomy 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 102000043136 MAP kinase family Human genes 0.000 description 8
- 108091054455 MAP kinase family Proteins 0.000 description 8
- 229940000406 drug candidate Drugs 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 241000206596 Halomonas Species 0.000 description 7
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 description 7
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 102000001267 GSK3 Human genes 0.000 description 6
- 108060006662 GSK3 Proteins 0.000 description 6
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 6
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000000392 somatic effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 5
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 5
- 108010008707 Mucin-1 Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 239000003124 biologic agent Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000004565 tumor cell growth Effects 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 101100224408 Mus musculus Dpep3 gene Proteins 0.000 description 4
- -1 NANOG Proteins 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000003255 drug test Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 101100079633 Mus musculus Nme6 gene Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000003590 rho kinase inhibitor Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 241001653918 Halomonas sp. Species 0.000 description 2
- 101001011886 Homo sapiens Matrix metalloproteinase-16 Proteins 0.000 description 2
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 2
- 101150076359 Mhc gene Proteins 0.000 description 2
- 101150051466 Nme7 gene Proteins 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000447 dimerizing effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000000441 neoplastic stem cell Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012879 subculture medium Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LOTUZERZUQHMGU-UHFFFAOYSA-N 2-butoxy-6-[(4-methoxyphenyl)methyl]-1h-pyrimidin-4-one Chemical compound N1C(OCCCC)=NC(=O)C=C1CC1=CC=C(OC)C=C1 LOTUZERZUQHMGU-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101150073904 CHD4 gene Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101100326315 Homo sapiens BRD4 gene Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101100327752 Homo sapiens CHD4 gene Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101150022089 JMJD6 gene Proteins 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 101150069947 Mbd3 gene Proteins 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 101100079638 Mus musculus Nme7 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102220484604 Nucleoside diphosphate kinase A_P96S_mutation Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000986839 Porphyromonas gingivalis W83 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940046257 glyceryl phosphate Drugs 0.000 description 1
- 101150090422 gsk-3 gene Proteins 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865092P | 2013-08-12 | 2013-08-12 | |
| US61/865,092 | 2013-08-12 | ||
| ??PCT/US14/17515 | 2014-02-20 | ||
| PCT/US2014/017515 WO2014130741A2 (en) | 2013-02-20 | 2014-02-20 | Nme inhibitors and methods of using nme inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201537172A TW201537172A (zh) | 2015-10-01 |
| TWI659210B true TWI659210B (zh) | 2019-05-11 |
Family
ID=52468797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103127591A TWI659210B (zh) | 2013-08-12 | 2014-08-12 | 加強腫瘤生長的方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP3038462B1 (enExample) |
| JP (2) | JP6640086B2 (enExample) |
| CN (1) | CN105764334B (enExample) |
| AU (2) | AU2014306778B2 (enExample) |
| CA (1) | CA2921187A1 (enExample) |
| IL (1) | IL244093B (enExample) |
| TW (1) | TWI659210B (enExample) |
| WO (1) | WO2015023694A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108513537A (zh) * | 2015-09-23 | 2018-09-07 | 米纳瓦生物技术公司 | 筛选分化干细胞的试剂的方法 |
| WO2018183654A1 (en) * | 2017-03-29 | 2018-10-04 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| CN108434452A (zh) * | 2018-03-13 | 2018-08-24 | 安徽瀚海博兴生物技术有限公司 | 一种将pd-1抗体和jmjd6联合用于制备抗癌药物的应用 |
| CN116075318A (zh) | 2020-06-26 | 2023-05-05 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| WO2023201234A2 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| WO2025049494A1 (en) | 2023-08-29 | 2025-03-06 | Minerva Biotechnologies Corporation | Bacterial nme7 orthologs and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272290A (zh) * | 2008-10-09 | 2011-12-07 | 米纳瓦生物技术公司 | 用于在细胞中诱导多能性的方法 |
| WO2012126013A2 (en) * | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| WO2013081188A1 (ja) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US20090214483A1 (en) * | 2005-06-30 | 2009-08-27 | Weinberg Robert A | Progenitor Cells and Uses Thereof |
| MX2008015492A (es) * | 2006-06-06 | 2009-02-12 | Univ Tennessee Res Foundation | Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen. |
| CN101855339A (zh) * | 2007-01-22 | 2010-10-06 | 雷文生物技术公司 | 人类癌症干细胞 |
| WO2012165287A1 (ja) * | 2011-05-27 | 2012-12-06 | 公立大学法人横浜市立大学 | 人工癌幹細胞の作製方法及びその分化誘導方法 |
| WO2013059373A2 (en) * | 2011-10-17 | 2013-04-25 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| CA2880010A1 (en) * | 2012-07-24 | 2014-01-30 | Minerva Biotechnologies Corporation | Nme variant species expression and suppression |
| KR20210082547A (ko) * | 2013-02-20 | 2021-07-05 | 미네르바 바이오테크놀로지 코포레이션 | Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법 |
-
2014
- 2014-08-12 EP EP14835875.7A patent/EP3038462B1/en active Active
- 2014-08-12 JP JP2016534802A patent/JP6640086B2/ja active Active
- 2014-08-12 WO PCT/US2014/050773 patent/WO2015023694A2/en not_active Ceased
- 2014-08-12 TW TW103127591A patent/TWI659210B/zh active
- 2014-08-12 CA CA2921187A patent/CA2921187A1/en active Pending
- 2014-08-12 EP EP23160947.0A patent/EP4233536A3/en active Pending
- 2014-08-12 CN CN201480055352.5A patent/CN105764334B/zh active Active
- 2014-08-12 AU AU2014306778A patent/AU2014306778B2/en active Active
-
2016
- 2016-02-11 IL IL244093A patent/IL244093B/en unknown
-
2019
- 2019-08-23 JP JP2019152467A patent/JP6902577B2/ja active Active
-
2021
- 2021-01-22 AU AU2021200429A patent/AU2021200429C1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102272290A (zh) * | 2008-10-09 | 2011-12-07 | 米纳瓦生物技术公司 | 用于在细胞中诱导多能性的方法 |
| WO2012126013A2 (en) * | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| WO2013081188A1 (ja) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | 誘導悪性幹細胞 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4233536A3 (en) | 2023-10-25 |
| AU2021200429B2 (en) | 2023-05-11 |
| IL244093A0 (en) | 2016-04-21 |
| AU2021200429A1 (en) | 2021-02-25 |
| CA2921187A1 (en) | 2015-02-19 |
| EP3038462B1 (en) | 2023-03-15 |
| JP6640086B2 (ja) | 2020-02-05 |
| AU2014306778B2 (en) | 2020-10-29 |
| AU2014306778A1 (en) | 2016-03-03 |
| JP6902577B2 (ja) | 2021-07-14 |
| IL244093B (en) | 2022-01-01 |
| JP2019213551A (ja) | 2019-12-19 |
| EP3038462A4 (en) | 2017-06-14 |
| WO2015023694A2 (en) | 2015-02-19 |
| JP2016527901A (ja) | 2016-09-15 |
| CN105764334A (zh) | 2016-07-13 |
| TW201537172A (zh) | 2015-10-01 |
| EP3038462A2 (en) | 2016-07-06 |
| CN105764334B (zh) | 2020-07-28 |
| WO2015023694A3 (en) | 2015-04-23 |
| EP4233536A2 (en) | 2023-08-30 |
| AU2021200429C1 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220193270A1 (en) | Method for enhancing tumor growth | |
| AU2021200429C1 (en) | Method for enhancing tumor growth | |
| McDougall et al. | Trop2: from development to disease | |
| CN104350145B (zh) | 用于无饲养细胞培养牛和猪的精原干细胞的方法 | |
| CN108884441B (zh) | 集落形成培养基及其用途 | |
| JP2023026679A (ja) | ヒストンｈ３－リジントリメチル化を除去することによって体細胞核移入（ｓｃｎｔ）効率を増加させるための方法および組成物 | |
| KR20170134634A (ko) | 상피 세포의 생체외 증식 | |
| US20180258186A1 (en) | NME Inhibitors and Methods of Using NME Inhibitors | |
| Wang et al. | GASZ promotes germ cell derivation from embryonic stem cells | |
| Dementyeva et al. | Applying patient-specific induced pluripotent stem cells to create a model of hypertrophic cardiomyopathy | |
| US20180235193A1 (en) | Method of stem cell-based organ and tissue generation | |
| US20190151371A1 (en) | Process for continuous cell culture of islet cells | |
| WO2009154265A1 (ja) | 癌幹細胞及び癌細胞株の製造方法 |